Complete loss of HLA class I antigen expression on melanoma cells:: A result of successive mutational events

被引:82
作者
Paschen, A
Méndez, RM
Jimenez, P
Sucker, A
Ruiz-Cabello, F
Song, MX
Garrido, F
Schadendorf, D
机构
[1] Univ Hosp Mannheim, German Canc Res Ctr, Skin Canc Unit, Mannheim, Germany
[2] Univ Granada, Hosp Virgen Nieves, Serv Anal Clin, Granada, Spain
关键词
immune escape; HLA loss; beta(2)-microglobulin; mutation chromosomal aberration;
D O I
10.1002/ijc.10906
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Alterations in the surface expression of HLA class I molecules have been described as a strategy of tumors to evade recognition by cytotoxic T cells. We detected complete loss of HLA class I antigen presentation for 2 tumor cell lines from 1 melanoma patient, the first originated from a regional lymph node lesion diagnosed simultaneously with the primary tumor and the second established 8 months later from a metastatic pleural effusion sample. Antigen presentation was not inducible with IFN-gamma but could be restored after transfection of tumor cells with b2m cDNA, indicating a defect in b2m expression. Analysis of the nature of this defect revealed that it originated from at least 2 mutational events affecting both copies of the b2m gene: a microdeletion of 498 bp in one b2m gene, including its entire exon 1, and a macrodeletion involving the entire copy of the second b2m gene. Microsatellite analysis pointed to the macrodeletion by demonstrating LOH for several specific markers on the long arm (q) of chromosome IS. Structural imbalance of 15q was verified by FISH. FISH studies also indicated the coexistence of a structurally abnormal variant of chromosome 15q with 2 apparently entire chromosomes 15q harboring the homozygous b2m microdeletion. Block of b2m expression in tumor cells builds a barrier to immunotherapy of cancer patients, and its early incidence should be of major consideration in the development and design of immunotherapeutic strategies. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:759 / 767
页数:9
相关论文
共 37 条
[1]   PRODUCTION OF MONOCLONAL ANTIBODIES TO GROUP-A ERYTHROCYTES, HLA AND OTHER HUMAN CELL-SURFACE ANTIGENS - NEW TOOLS FOR GENETIC-ANALYSIS [J].
BARNSTABLE, CJ ;
BODMER, WF ;
BROWN, G ;
GALFRE, G ;
MILSTEIN, C ;
WILLIAMS, AF ;
ZIEGLER, A .
CELL, 1978, 14 (01) :9-20
[2]   Mutations of the β2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides [J].
Benitez, R ;
Godelaine, D ;
Lopez-Nevot, MA ;
Brasseur, F ;
Jiménez, P ;
Marchand, M ;
Oliva, MR ;
van Baren, N ;
Cabrera, T ;
Andry, G ;
Landry, C ;
Ruiz-Cabello, F ;
Boon, T ;
Garrido, F .
TISSUE ANTIGENS, 1998, 52 (06) :520-529
[3]   ALTERED BINDING OF REGULATORY FACTORS TO HLA CLASS-I ENHANCER SEQUENCE IN HUMAN TUMOR-CELL LINES LACKING CLASS-I ANTIGEN EXPRESSION [J].
BLANCHET, O ;
BOURGE, JF ;
ZINSZNER, H ;
ISRAEL, A ;
KOURILSKY, P ;
DAUSSET, J ;
DEGOS, L ;
PAUL, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (08) :3488-3492
[4]   STIMULATION OF HLA-A,B,C BY IFN-ALPHA - THE DERIVATION OF MOLT-4 VARIANTS AND THE DIFFERENTIAL EXPRESSION OF HLA-A,B,C SUBSETS [J].
BURRONE, OR ;
KEFFORD, RF ;
GILMORE, D ;
MILSTEIN, C .
EMBO JOURNAL, 1985, 4 (11) :2855-2860
[5]   LACK OF HLA CLASS-I ANTIGEN EXPRESSION BY CULTURED MELANOMA-CELLS FO-1 DUE TO A DEFECT IN B2M GENE-EXPRESSION [J].
DURSO, CM ;
WANG, ZG ;
CAO, Y ;
TATAKE, R ;
ZEFF, RA ;
FERRONE, S .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 87 (01) :284-292
[6]   Defective death receptor signaling as a cause of tumor immune escape [J].
French, LE ;
Tschopp, J .
SEMINARS IN CANCER BIOLOGY, 2002, 12 (01) :51-55
[7]  
Garcia-Lora A, 2001, INT J CANCER, V91, P109, DOI 10.1002/1097-0215(20010101)91:1<109::AID-IJC1017>3.0.CO
[8]  
2-E
[9]   MHC antigens and tumor escape from immune surveillance [J].
Garrido, F ;
Algarra, I .
ADVANCES IN CANCER RESEARCH, VOL 83, 2001, 83 :117-158
[10]   Implications for immunosurveillance of altered HLA class I phenotypes in human tumours [J].
Garrido, F ;
RuizCabello, F ;
Cabrera, T ;
PerezVillar, JJ ;
LopezBotet, M ;
DugganKeen, M ;
Stern, PL .
IMMUNOLOGY TODAY, 1997, 18 (02) :89-95